110 related articles for article (PubMed ID: 8683891)
41. A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: role of maintenance and long-term follow-up.
Levi JA; Thomson D; Sandeman T; Tattersall M; Raghavan D; Byrne M; Gill G; Harvey V; Burns I; Snyder R
J Clin Oncol; 1988 Jul; 6(7):1154-60. PubMed ID: 2455778
[TBL] [Abstract][Full Text] [Related]
42. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
Grimison PS; Stockler MR; Thomson DB; Olver IN; Harvey VJ; Gebski VJ; Lewis CR; Levi JA; Boyer MJ; Gurney H; Craft P; Boland AL; Simes RJ; Toner GC
J Natl Cancer Inst; 2010 Aug; 102(16):1253-62. PubMed ID: 20631341
[TBL] [Abstract][Full Text] [Related]
43. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival.
McCaffrey JA; Mazumdar M; Bajorin DF; Bosl GJ; Vlamis V; Motzer RJ
J Clin Oncol; 1997 Jul; 15(7):2559-63. PubMed ID: 9215825
[TBL] [Abstract][Full Text] [Related]
44. Cisplatin containing combination chemotherapy of advanced germ cell line testicular tumours.
Bodrogi I; Baki M; Horti J; Géczi L; Liszka G; Ottó S; Hindy I; Eckhardt S; Sugár J
Acta Med Hung; 1994; 50(3-4):275-92. PubMed ID: 8587840
[TBL] [Abstract][Full Text] [Related]
45. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
Fléchon A; Biron P; Philip I; Blay JY; Droz JP
Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344
[TBL] [Abstract][Full Text] [Related]
46. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
47. Cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis.
Johnson E
J Clin Oncol; 1991 Jun; 9(6):1092-4. PubMed ID: 1709684
[No Abstract] [Full Text] [Related]
48. [Germ cell tumor].
Kasai M; Kiyama Y
Gan To Kagaku Ryoho; 1995 Oct; 22(12):1749-55. PubMed ID: 7574805
[TBL] [Abstract][Full Text] [Related]
49. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.
de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Fosså SD; Cook P; de Prijck L; Stenning S; Collette L
J Clin Oncol; 2001 Mar; 19(6):1629-40. PubMed ID: 11250991
[TBL] [Abstract][Full Text] [Related]
50. The importance of dose intensity in chemotherapy of advanced testicular cancer.
Miyanaga N; Akaza H; Hattori K; Takeshima H; Koiso K
Urol Int; 1995; 54(4):220-5. PubMed ID: 7541924
[TBL] [Abstract][Full Text] [Related]
51. [Management of advanced seminoma: retrospective study of 96 patients].
Bompas E; Fléchon A; Biron P; Droz JP
Bull Cancer; 2002 Oct; 89(10):877-85. PubMed ID: 12441279
[TBL] [Abstract][Full Text] [Related]
52. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
53. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
[TBL] [Abstract][Full Text] [Related]
54. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer.
Berger CC; Bokemeyer C; Schneider M; Kuczyk MA; Schmoll HJ
Eur J Cancer; 1995 Dec; 31A(13-14):2229-38. PubMed ID: 8652248
[TBL] [Abstract][Full Text] [Related]
55. Testicular cancer and the legacy of chemotherapy.
Muggia FM
Cancer Chemother Pharmacol; 1985; 15(1):1-5. PubMed ID: 2408772
[TBL] [Abstract][Full Text] [Related]
56. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
[TBL] [Abstract][Full Text] [Related]
57. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20).
Fosså SD; de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Cook P; de Prijck L; Stenning S; Aaronson NK; Bottomley A; Collette L; ;
J Clin Oncol; 2003 Mar; 21(6):1107-18. PubMed ID: 12637478
[TBL] [Abstract][Full Text] [Related]
58. An alternative treatment regimen of advanced seminoma with carboplatin, etoposide, and bleomycin instead of cisplatin-based therapy.
Giesen E; Mager A; van Tinteren H; Rodenhuis S; Kerst JM
Urol Oncol; 2013 Jan; 31(1):110-4. PubMed ID: 21458311
[TBL] [Abstract][Full Text] [Related]
59. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen.
Ghosn M; Droz JP; Theodore C; Pico JL; Baume D; Spielmann M; Ostronoff M; Moran A; Salloum E; Kramar A
Cancer; 1988 Jul; 62(1):24-7. PubMed ID: 3133101
[TBL] [Abstract][Full Text] [Related]
60. [Refractory germ cell cancer of testis treated by salvage high-dose chemotherapy: report of three cases].
Tanji S; Obara W; Sugimura J; Ohmori S; Matsushita Y; Tokunaga H; Konda R; Fujioka T; Murai K; Ishida Y
Hinyokika Kiyo; 2004 Feb; 50(2):77-80. PubMed ID: 15101160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
